Cancer cells have learned to disguise themselves as healthy cells by displaying the CD47 “don’t eat me” signal on their surface. This signals macrophages to spare the cancer cell from phagocytosis. For researchers studying tumor immune evasion, understanding and disrupting the CD47/SIRPalpha axis has become critical for designing next-generation cancer immunotherapies.
The CD47 Don’t-Eat-Me Signal
Signal Regulatory Protein alpha (SIRPalpha) sits on the surface of macrophages and other myeloid cells, acting as a brake on phagocytosis. When SIRPalpha engages CD47 on the surface of a cell, it delivers an inhibitory signal that tells the macrophage to back off. Normal healthy cells display CD47 at physiological levels, and macrophages respect this signal, only clearing truly apoptotic or pathogenic cells.
Cancer cells exploit this normal homeostatic mechanism by overexpressing CD47. This transforms the cancer cell’s surface into a biochemical shield, converting a danger signal into an immunity evasion mechanism. Tumor-associated macrophages, already skewed toward pro-tumoral phenotypes, readily accept the CD47 signal and refrain from eliminating cancer cells. This represents one of the most elegant examples of immune system hijacking in cancer biology.
Macrophage Biology and Tumor Clearance
Macrophages are formidable tumor killers when permitted to engage. These professional phagocytes can engulf entire cancer cells, process tumor antigens, and present them to T cells, initiating adaptive immune responses. However, if the CD47/SIRPalpha brake is engaged, macrophages disengage despite strong signals to attack.
Tumor-associated macrophages further complicate the picture. These myeloid cells become reprogrammed through chronic exposure to tumor-derived factors, often adopting pro-tumoral functions including angiogenesis promotion, extracellular matrix remodeling, and direct immunosuppression. Even when CD47 brake is removed, some tumor-associated macrophages may not immediately switch to tumor-killing phenotypes.
This complexity makes the CD47/SIRPalpha axis an attractive therapeutic target: removing the CD47 brake could awaken innate anti-tumor immunity in macrophages, while simultaneously providing signals to reprogram tumor-associated macrophage phenotypes.
Antibody vs. Small Molecule Approaches
Early development focused on monoclonal antibodies blocking CD47 or SIRPalpha. Magrolimab, an anti-CD47 antibody, reached clinical development and demonstrated measurable anti-tumor activity, particularly in hematological malignancies. However, clinical development has faced challenges. In 2023, the ASPEN-02 program evaluating Evorpacept (another anti-CD47 antibody) in combination with azacitidine for myelodysplastic syndromes showed insufficient improvement compared to azacitidine alone, demonstrating that CD47 targeting alone may not overcome all immunosuppressive mechanisms in solid tumors.
These clinical setbacks have accelerated interest in small-molecule inhibitors of the CD47-SIRPalpha interaction. Small molecules offer advantages over antibodies: they can achieve oral bioavailability, penetrate tissue barriers more effectively, and potentially reach intracellular pools of CD47. Additionally, their shorter half-lives provide flexible control over in vivo pathway modulation.
Small Molecule Development Progress
A 2024 breakthrough study published in Cell Communication and Signaling described SMC18, a small molecule inhibitor of both the CD47/SIRPalpha interaction and the PD-1/PD-L1 checkpoint. This dual-function compound significantly enhanced macrophage phagocytosis of tumor cells while simultaneously restoring CD8+ T cell infiltration and function. When combined with radiotherapy, SMC18 demonstrated enhanced anti-tumor efficacy in preclinical models.
AUR103 represents an oral small molecule CD47 antagonist currently in Phase 1 clinical development, demonstrating that oral bioavailability of CD47 inhibitors is achievable. These compounds confirm that disrupting the CD47-SIRPalpha interface is pharmacologically feasible with small molecules.
Mechanistic Advantages of Targeting CD47/SIRPalpha
Targeting the CD47/SIRPalpha axis activates anti-tumor immunity through multiple mechanisms. Direct macrophage activation enables phagocytosis of tumor cells, triggering cross-presentation of tumor antigens to T cells. This enhanced antigen presentation can synergize with checkpoint inhibitors, creating feedback loops where macrophage activation strengthens T cell responses.
Additionally, CD47 overexpression on tumor cells creates selective pressure for cancer cell evolution. Removing the CD47 brake permits macrophage-mediated selection, potentially eliminating CD47-high, immunoevasive tumor populations while allowing less aggressive, lower-CD47-expressing cells to be controlled by adaptive immunity.
Combination Strategies and Future Development
Current research increasingly combines CD47 targeting with checkpoint inhibitors, radiotherapy, and targeted therapies. Each combination may activate different immune mechanisms: radiotherapy induces immunogenic cell death, checkpoint inhibitors enhance T cell responses, and CD47 antagonists awaken macrophage anti-tumor activity. Together, these approaches address multiple layers of tumor immune evasion.
Research into why the ASPEN-02 trial failed for CD47-targeting antibodies continues informing next-generation strategies. The field increasingly recognizes that CD47-driven immune evasion works best in combination with multiple other immunosuppressive mechanisms. Researchers now map the complete immunosuppressive landscape before designing CD47-targeted approaches.
Immunomart provides CD47 antagonists and SIRPalpha-targeting compounds for mechanistic research into macrophage-mediated tumor immunity. Whether investigating phagocytosis mechanisms, evaluating combination effects with checkpoint inhibitors, or studying tumor evolutionary dynamics under immune pressure, having characterized research tools accelerates progress.
Looking Forward
The CD47/SIRPalpha axis remains an attractive target despite early clinical setbacks with antibody approaches. Small-molecule inhibitors with improved tissue penetration and oral bioavailability may overcome limitations of macromolecular approaches. The field continues advancing through better mechanistic understanding of tumor-macrophage interactions and rational design of multi-targeting combination strategies.
CD47 antagonists exemplify how understanding immune evasion mechanisms can drive therapeutic innovation. Researchers investigating this axis contribute to the broader mission of converting immunologically cold tumors into targets susceptible to innate and adaptive anti-tumor immunity.
Research Use Only Disclaimer: All small molecule inhibitors and research compounds mentioned in this article are intended for laboratory research use only (RUO). They are not approved for human or veterinary use, not intended for diagnostic or therapeutic purposes, and must not be used as drugs, food additives, or household chemicals. Always follow your institution’s safety protocols when handling research compounds.
